A股异动 | 长春高新(000661.SZ)涨逾6% 一季度预增55%-65%叠加券商看好
格隆汇3月30日丨长春高新(000661.SZ)快速拉升,现报468.5元,涨幅6.13%,最新总市值1896.11亿元,近六个交易日累计涨约20%。公司29日公告称,预计今年一季度归属于上市公司股东的净利润8.41亿元-8.95亿元,同比增长55%-65%,主要原因是控股骨干医药企业收入增长。华西证券指,公司2021Q1业绩表现靓丽,生长激素恢复高增长;百克鼻喷流感疫苗放量,研发管线值得期待。预计2021-2023年归母净利润为41.0/51.0/61.4/亿元,对应PE分别为44/35/29倍,维持“买入”评级。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.